Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)Ryan B. Corcoran, Eric Van Cutsem, Salvatore Siena et al.|Annals of Oncology|2016Cited by 46
Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer ModelsMatthew Squires, Neil T. Thompson|Molecular Cancer Therapeutics|2011Cited by 32
Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with <i>BRAF</i> V600–mutant melanoma.Paul B. Chapman, Axel Hauschild, Paolo A. Ascierto et al.|Journal of Clinical Oncology|2017Cited by 6
Abstract CT087: Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with <i>BRAF</i> V600E/K-mutant melanoma in the COMBAT trialCaroline Robert, Jean‐Jacques Grob, Delphine Allard et al.|Cancer Research|2018Cited by 1